May 4th, 2016|
The Food and Drug Administration (FDA) has issued a new warning that links the use of Aripiprazole (Abilify, Abilify Maintena, Aristada) with compulsive or uncontrollable urges such as binge eating, excessive shopping, gambling, and an increase in sex drive. Abilify® users reported that these behaviors stopped when the medicine was discontinued or the dose was reduced. Cory Watson Attorneys is representing hundreds of Abilify® victims nationwide.
According to the May 3, 2016, FDA safety announcement, “pathological gambling is listed as a reported side effect in the current aripiprazole drug labels, this description does not entirely reflect the nature of the impulse-control risk FDA identified. In addition, FDA has become aware of other compulsive behaviors associated with aripiprazole, such as compulsive eating, shopping, and sexual actions. These compulsive behaviors can affect anyone who is taking the medicine. As a result, FDA is adding new warnings about all of these compulsive behaviors to the drug labels and the patient Medication Guides for all aripiprazole products.”
The May 3 FDA Abilify® warning is the strongest warning to date about risks associated with the popular drug Abilify®, prescribed to treat certain mental disorders, including schizophrenia, bipolar disorder, Tourette’s disorder, and irritability associated with autistic disorder. There is help available for Abilify® users who have suffered as a result of taking the drug. The experienced drug injury lawyers at Cory Watson Attorneys are representing people injured by the drug Abilify® and are available for a free consultation. Please consult with your doctor before stopping or changing any prescription medication.